People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology, Biotech, Software / Tech, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vizgen, Inc. | — | Biotechnology | Series D+ | $295.1M | $319.9M | 2021 |
| Octave Bioscience Inc | — | Biotech | Series B | $105.8M | $169.3M | 2020 |
| Ultivue, Inc. | — | Biotechnology | Series B | $55.2M | $23.4M | 2024 |
| General Automation Lab Technologies Inc. | — | Software / Tech | Series A | $38.5M | $337.7M | 2020 |
| NanoView Biosciences, Inc. | — | Biotechnology | Series A | $17.5M | $41.2M | 2020 |
| Outcomes4Me Inc. | — | Other Technology | Series A | $16.5M | $241.8M | 2021 |
Andrea Jackson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrea Jackson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Keith Crandell | 2 | 11 |
| Michael Rubin | 2 | 8 |
| Matthew Posard | 2 | 4 |
| Robert Carson | 2 | 3 |
| PAUL CONLEY | 1 | 17 |
| Brook Byers | 1 | 13 |
| David Walt | 1 | 6 |
| Thomas Hawes | 1 | 6 |
| Ian Ratcliffe | 1 | 6 |
| David R. Walt | 1 | 5 |
| David Fleshman | 1 | 5 |
| Paxton Major | 1 | 5 |
| William Hagstrom | 1 | 4 |
| George Scangos | 1 | 4 |
| Mark Weeks | 1 | 4 |
| Michael Pellini | 1 | 4 |
| Fenel Eloi | 1 | 3 |
| Peng Yin | 1 | 3 |
| Michael Natan | 1 | 3 |
| Marijn E. Dekkers | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.